Monitoring Viral Suppression when switching from fixed dose combination efavirenz, emtricitabine and tenofovir (Atripla) to fixed dose combination elvitegravir, cobicistat, emtricitabine, and tenofovir (Stribild) in virologically suppressed adults with HIV
A Phase IV, prospective, observational cohort study examining patients changed from Atripla to
Stribild for continued suppression of viral load, effect on CD-4 cells, quality of life and sleep using
blood tests and standardized questionnaires. While continuing to control the virus to acceptable
levels, CD 4 counts were noted to rise and patients experienced fewer CNS side effects. Sleep quality
was also improved.
